Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms STEP 4
- Sponsors Novo Nordisk
- 26 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2018 According to a Novo Nordisk media release, all four STEP trials are expected to be completed in 2020.
- 07 Jun 2018 Status changed from not yet recruiting to recruiting.